Physician profile
Tilak Shah
NPI 1568629228
$20,272.00
in general payments reported to CMS, 2019-2025
16 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.41 · 2022: $2,056 · 2023: $14K · 2024: $2,976 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $2,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,729.74 |
| Food and Beverage | $2,461.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Endoscopy | $16,879.74 | 2022-2025 | |
| Steris Corporation | $1,488.12 | 2023-2025 | |
| Abbvie INC. | $993.42 | 2023-2025 | Viberzi, Linzess, Rinvoq |
| Boston Scientific Corporation | $358.37 | 2022-2025 | Wallflex Duodenal, Watchman Flx, Agile Esophageal |
| Regeneron Pharmaceuticals, INC. | $136.07 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $79.61 | 2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.03 | 2024 | Xifaxan |
| Ardelyx, INC. | $59.60 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $55.62 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.81 | 2023-2025 | Entyvio, Eohilia |
| Cook Medical LLC | $24.41 | 2019 | |
| Pentax of America, INC. | $19.94 | 2023 | C2 Cryoballoon |
| Coloplast Corp | $17.74 | 2025 | |
| Intercept Pharmaceuticals, INC. | $16.44 | 2025 | |
| Intra-Sana Laboratories | $12.08 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tilak Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.